Dr Reddy’s, Immutep Sign Efti Licensing Deal Covering Markets Outside North America, Europe, Japan and Greater China

Overview

• The exclusive agreement gives Dr Reddy’s development and commercialisation rights to Eftilagimod Alfa in all countries outside North America, Europe, Japan and Greater China.
• Immutep will receive a $20 million upfront payment and is eligible for up to $349.5 million in regulatory and commercial milestones plus double‑digit royalties on sales in the licensed markets.
• Immutep keeps all rights in key markets including North America, Europe and Japan and will supply Efti globally under its retained manufacturing rights.
• Efti is a first‑in‑class immunotherapy in late‑stage evaluation for first‑line advanced or metastatic non‑small cell lung cancer and is being studied in head and neck, breast and soft tissue sarcoma.
• Dr Reddy’s shares closed 0.68% lower on the NSE following the announcement, and executives from both companies said the partnership aligns product innovation with market access strengths.